U.S. Drug Safety Study to Be Released by the Pew Health Group

On Tuesday, July 12, the Pew Health Group will host a policy forum for Congressional staffers to release a report on U.S. drug safety. The Pew study takes an in-depth look at the risks associated with an increasingly complex, globalized and outsourced pharmaceutical supply chain and recommends ways policy makers can make medicine supply safer for patients.  

Following a presentation of the white paper, After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs, Allan Coukell, a pharmacist and director of medical programs at the Pew Health Group, will moderate a panel discussion with executives from the pharmaceutical industry and the U.S. Food and Drug Administration.

WHO:  Allan Coukell, director of medical programs, Pew Health Group (moderator)

Panelists:
Deborah Autor, Esq., director, Office of Compliance, the Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Heather Bresch, president, Mylan, one of the world's largest generics and specialty pharmaceutical company
John Gray, president and CEO, Healthcare Distribution Management Association, which represents major U.S. pharmaceutical distributors

WHAT:  Policy forum to release white paper on U.S. drug safety

WHEN:  Tuesday, July 12, 2011
11:00 a.m.12:00 p.m.

Doors open at 10:30 a.m.  

WHERE:  Dirksen Senate Office Building
1st & C Streets, NE
Washington, D.C. 20002

Health, Education, Labor & Pensions Committee Room, SD-430

Link to Webcast: http://www.fci.tv/webcast/pew/07-12-11

The Pew Health Group is the health and consumer-product safety arm of The Pew Charitable Trusts, a nonprofit organization that applies a rigorous, analytical approach to improve public policy, inform the public and stimulate civic life. For more information, please visit www.prescriptionproject.org.

CONTACT: LINDA PARIS, PEW HEALTH GROUP
202-540-6354 | [email protected]

/PRNewswire-USNewswire -- July 8, 2011/

SOURCE Pew Health Group

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.